Page 292 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C1.7. Tumor characteristics—stage (continued)
Author Database Stage groups 1980-84 1985- 1990-94 1995-99 2000-04 2005- Statistical Notes
Year 89 10 analysis
PMID
75
Mettlin NCDB Stage
1998 0 5.4% 2.0% NR
9781963 I 22.8% 24.9%
II 41.1% 49.7%
III 18.0% 13.0%
IV 12.6% 10.3%
Localized disease 69.3% 76.7%
(0-II) (1992) (1995)
91
Mettlin NCDB AJCC stage NR
1999 0 4.5% 2%
10547563 I 19% 23.5%
II 34% 46%
III 15% 12%
IV 10% 8%
Unknown 18% 8%
(1992) (1996)
76
Danley LAC/USC Localized 71% 66% 1.03 (0.96,
1995 CSP Regional/Metastatic 29% 34% 1.10)
8580296 Percentage of (1981- (1985- 1.29 (1.21,
cases by yr of 84) 88) 1.37)
diagnosis (OR and 95%
CIs using
1976-80 as the
baseline
period)

P<0.001 for
trend over time
Ordering of the studies follows Appendix Table C1.1.
AJCC = American Joint Committee on Cancer; cAJC = clinical stage according to American Joint Committee on Cancer guidelines; CI = confidence interval; NA = not applicable;
NR = not reported; OR = odds ratio; pAJCC = pathological stage according to American Joint Committee on Cancer guidelines; PMID = PubMed identification number; PSA =
prostate-specific antigen; SD = standard deviation.

C-64